DRUG
Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying
Status
Completed
Phase
Phase 2
Enrollment
39
Locations
2
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
Impact of combined Lantus (insulin glargine) and Lyxumia(lixisenatide) on insulin secretion and gastric emptying
Full detailed description
Impact of combined Lantus (insulin glargine) and Lyxumia(lixisenatide) on insulin secretion and gastric emptying
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
Jul 29, 2013
Study start
Dec 2013
Primary completion
Oct 2014
Study completion
Oct 2014
Results posted
Not reported
Registry updated
Jan 22, 2015
Outcomes
What the study measures.
Primary outcomes
AUCISEC(0-10min)
Time frame · Within 0 to 10 min after iv glucose challenge
Secondary outcomes
Not reported in the indexed record.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Patients with type 2 diabetes mellitus diagnosed at least one year before the screening visit not previously treated with glitazones, insulin or GLP-1 agonists * Inadequately controlled diabetes mellitus Exclusion Criteria: * Subjects with type 1 diabetes, maturity onset diabetes of the young (MODY) or secondary forms of diabetes such as due to pancreatitis
Study locations
2 registered sites.
Germany. Showing up to 24 locations stored in the fast local snapshot.
St. Josef-Hospital, University Hospital, Ruhr
Bochum, Germany
Profil Institut für Stoffwechselforschung GmbH
Neuss, Germany
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Lixisenatide.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
Sanofi · Type 2 Diabetes
Phase 4
Completed
105
2026-07
Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
Shanghai Zhongshan Hospital · Type 2 Diabetes
Phase 4
Recruiting
1,316
2026-07
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
Brigham and Women's Hospital · Cardiovascular Events · Type2 Diabetes
Not applicable
Active, not recruiting
781,430
2026-05
iGlarLixi CGM Study in Chinese T2D Individuals After OADs
Sanofi · Type 2 Diabetes (T2D)
Phase 4
Recruiting
678
2026-03
Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes
Yanbing Li · Type 2 Diabetes
Phase 4
Not yet recruiting
324
2026-02
Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease
University Hospital, Toulouse · Parkinson Disease
Phase 2
Completed
156
2025-11
iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)
Sanofi · Type 2 Diabetes Mellitus
Phase 3
Completed
582
2025-09
Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
Ohio State University · Cardiovascular Kidney Metabolic Syndrome
Not applicable
Active, not recruiting
23,280,000
2025-09
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.